[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335844-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335844-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-cost-effectiveness-analysis-of-lung-cancer-screening-with-low-dose-computed-tomography-and-a-polygenic-risk-score","A cost-effectiveness analysis of lung cancer screening with low-dose computed tomography and a polygenic risk score","","A cost-effectiveness study evaluates lung cancer screening strategies that combine low-dose computed tomography (LDCT) with a polygenic risk score (PRS) versus strategies without PRS. A Markov state-transition model follows a hypothetical cohort of 300,000 heavy smokers aged 50–74 for annual cycles until death or age 79, adopting a societal perspective with parameters from local medical insurance databases and validated transition probabilities. Results compare ICER/ICUR across PRS-inclusive and LDCT-only strategies, supplemented by sensitivity and scenario analyses, and conclude PRS conjunctive screening is not cost-effective under a 1×GDP per-capita threshold.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-cost-effectiveness-analysis-of-lung-cancer-screening-with-low-dose-computed-tomography-and-a-polygenic-risk-score/335844/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-cost-effectiveness-analysis-of-lung-cancer-screening-with-low-dose-computed-tomography-and-a-polygenic-risk-score/335844.png","ImageObject",300,407,{"name":42,"@type":43},"Jiven","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What question does the study address about lung cancer screening?","Question",{"text":63,"@type":64},"It assesses the comparative cost-effectiveness of lung cancer screening strategies using LDCT with or without a polygenic risk score (PRS).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the analysis performed?",{"text":68,"@type":64},"A Markov state-transition model evaluated potential effects and costs for a hypothetical cohort of 300,000 heavy smokers, using annual cycles and a societal perspective, with sensitivity and scenario analyses.",{"name":70,"@type":61,"acceptedAnswer":71},"Which strategy was most cost-effective and what was the key conclusion about PRS?",{"text":72,"@type":64},"Annual LDCT-only screening from ages 70–74 was the most cost-effective. The PRS-based conjunctive screening strategy was not cost-effective under the willingness-to-pay threshold of 1×GDP per capita.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335844,1790261596,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":4},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","Zhao et al. BMC Cancer (2024) 24:73  \n[https://doi.org/10.1186/s12885-023-11800-7](https://doi.org/10.1186/s12885-023-11800-7)  \nBMC Cancer  \n RESEARCH Open Access  \nA cost-effectiveness analysis of lung cancer screening with low-dose computed tomography and a polygenic risk score  \nZixuan Zhao1, Shuyan Gu2, Yi Yang3, Weijia Wu3, Lingbin Du4, Gaoling Wang1* and Hengjin Dong3*  \nAbstract  \nIntroduction Several studies have proved that Polygenic Risk Score (PRS) is a potential candidate for realizing precision screening. The effectiveness of low-dose computed tomography (LDCT) screening for lung cancer has been proved to reduce lung cancer specific and overall mortality, but the cost-effectiveness of diverse screening strategies remained unclear.  \nMethods The comparative cost-effectiveness analysis used a Markov state-transition model to assess the potential effect and costs ofthe screening strategies incorporating PRS or not. A hypothetical cohort of 300,000 heavy smokers entered the study at age 50–74 years and were followed up until death or age 79 years. The model was run with a cycle length of 1 year. All the transition probabilities were validated and the performance value of PRS was extracted from published literature. A societal perspective was adopted and cost parameters were derived from databases of local medical insurance bureau. Sensitivity analyses and scenario analyses were conducted. Results The strategy incorporating PRS was estimated to obtain an ICER of CNY 156,691 .93 to CNY 221,741 .84 per QALY gained compared with non-screening with the initial start age range across 50–74 years. The strategy that screened using LDCT alone from 70–74 years annually could obtain an ICER of CNY 80,880 .85 per QALY gained, which was the most cost-effective strategy. The introduction of PRS as an extra eligible criteria was associated  \nwith making strategies cost-saving but also lose the capability of gaining more LYs compared with LDCT screening alone.  \nConclusion The PRS-based conjunctive screening strategy for lung cancer screening in China was not cost-effective using the willingness-to-pay threshold of 1 time Gross Domestic Product (GDP) per capita, and the optimal screening strategy for lung cancer still remains to be LDCT screening for now. Further optimization of the screening modality can be useful to consider adoption of PRS and prospective evaluation remains a research priority.  \nKeywords Cost-effectiveness, Lung cancer, Polygenic Risk Score, LDCT screening, Markov modelling  \n*Correspondence: Gaoling Wang [280097@njucm.edu.cn](280097@njucm.edu.cn)[ ](280097@njucm.edu.cn)Hengjin Dong [donghj@zju.edu.cn](donghj@zju.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ()[. The Creative Commons Public Domain Dedication waiver (](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ()[http://creativecom](http://creativecom)[mons.org/publicdomain/zero/1.0/](mons.org/publicdomain/zero/1.0/)) ","cbCaiawYpWxOPuZz","https://ap.wps.com/l/cbCaiawYpWxOPuZz","pdf",1362483,12,"English","# Abstract\n# Introduction\n# Methods\n# Results\n# Conclusion\n# Summary\n## Evidence before this study\n## Added value of this study","[{\"question\":\"What question does the study address about lung cancer screening?\",\"answer\":\"It assesses the comparative cost-effectiveness of lung cancer screening strategies using LDCT with or without a polygenic risk score (PRS).\"},{\"question\":\"How was the analysis performed?\",\"answer\":\"A Markov state-transition model evaluated potential effects and costs for a hypothetical cohort of 300,000 heavy smokers, using annual cycles and a societal perspective, with sensitivity and scenario analyses.\"},{\"question\":\"Which strategy was most cost-effective and what was the key conclusion about PRS?\",\"answer\":\"Annual LDCT-only screening from ages 70–74 was the most cost-effective. The PRS-based conjunctive screening strategy was not cost-effective under the willingness-to-pay threshold of 1×GDP per capita.\"}]","A cost-effectiveness analysis of lung cancer screening with low-dose computed tomography and a polygenic risk score | PDF",1790012552]